The chemical company argues that Apollo persuaded Huntsman to dropout of a June 2007 takeover deal with the Holland-based Basell by falsely indicating it would buy Huntsman at a better price, when in fact Apollo was acting out a broader plan to mar the transaction process so badly that it would compel Huntsman to come to Hexicon at a lower price.